BeStock  
Stocks › Biotechnology › TARS

Tarsus Pharmaceuticals TARS

US equityMarket cap rank #2295Biotechnology
$73.01 −$4.66 (-6.00%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $71.00 -2.75%
Open$77.09
Prev close$77.67
Day range$72.57 – $78.11
Volume706.8K
Market cap$3.60B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership108.1%-5.42 pts vs. prior quarter
Institutions holding323+3 vs. prior quarter
Insider trades (recent)26 buys / 21 sellsNet buying
Short interest12.96% of floatDays to cover 6.9 · as of 30 Oct 2026
Short-sale volume share18.9%5-day average of daily volume

Short-sale volume as % of daily volume

4%15%26%37%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$2.99M (9 inflow days, 11 outflow days).

Net flow by order size, last 20 sessions

−$3.1MSuper+$68.5KBig+$548.7KMid+$2.3MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 34.4% of shares outstanding.

Largest holders

  • BlackRock7.84%
  • Deep Track Capital, LP7.44%
  • RTW Investments, LP6.81%
  • FMR6.64%
  • Janus Henderson Group plc5.70%
  • Paradigm Biocapital Advisors LP5.63%
  • Vanguard Capital Management, LLC3.81%
  • Morgan Stanley3.47%

By investor type

  • Mutual Fund61.11%
  • Hedge Fund23.71%
  • VC/PE Fund9.83%
  • Public Company8.99%
  • Private Company2.89%
  • Individual/Insider2.75%
  • Government Pension Fund0.74%
  • Endowment Fund0.48%

Reported short interest has fallen from 13.67% to 12.96% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
FMR Mutual Fund 2026/Q3 +2,600,351 6.6%
abrdn plc Mutual Fund 2026/Q3 +505,591 1.0%
UBS Asset Management Mutual Fund 2026/Q3 +398,450 1.1%
Barclays PLC Public Company 2026/Q3 +226,653 0.5%
Wasatch Advisors LP Mutual Fund 2026/Q3 +99,473 0.9%
Invesco Capital Management LLC Mutual Fund 2026/Q3 +95,285 0.5%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +85,945 3.8%
Millennium Management LLC Hedge Fund 2026/Q3 +862,545 2.9%
Vestal Point Capital, LP Hedge Fund 2026/Q3 +850,000 2.1%
Janus Henderson Group plc Mutual Fund 2026/Q3 +567,833 5.7%
MFS Investment Management Mutual Fund 2026/Q3 +427,008 1.0%
Tang Capital Management, LLC Mutual Fund 2026/Q3 +379,642 3.2%
Wasatch Advisors LP Mutual Fund 2026/Q3 +368,568 0.8%
The Goldman Sachs Group, Inc. Public Company 2026/Q3 +356,153 1.4%
BlackRock Mutual Fund 2026/Q3 +303,525 8.8%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
2 Nov 2026 Neera Clase Chief Commercial Officer Other Derivative Acquisition +6,678 – 6,678
2 Nov 2026 Neera Clase Chief Commercial Officer Other Derivative Acquisition +10,587 $72.64 10,587
31 Oct 2026 Neera Clase Chief Commercial Officer Initial Statement of Beneficial +0 – 76,862
14 Sep 2026 William Link Independent Director Automatic Disposition -12,299 $80.01 94,487
14 Sep 2026 William Link Independent Director Derivative Exercise and Sale -201 $78.33 94,487
14 Sep 2026 David E. Pyott Independent Director Derivative Exercise and Retained +201 – 9,575
14 Sep 2026 Wendy Yarno Lead Independent Director Derivative Exercise and Retained +302 – 16,956
3 Sep 2026 Bobak Azamian Chairperson & CEO Automatic Disposition -10,000 $91.27 861,412
3 Sep 2026 Seshadri Neervannan Chief Operating Officer Open Market Disposition -4,564 $85.00 79,007
3 Sep 2026 Elizabeth Yeu-Lin Chief Medical Officer Automatic Disposition -13,953 $90.00 16,177
1 Sep 2026 Bobak Azamian Chairperson & CEO Automatic Disposition -10,000 $80.06 871,412
1 Sep 2026 Aziz Mottiwala Former Chief Commercial Officer Intent to Sell (Form 144) -8,000 $81.80 –
1 Sep 2026 Elizabeth Yeu-Lin Chief Medical Officer Intent to Sell (Form 144) -5,387 $80.00 –
1 Sep 2026 Elizabeth Yeu-Lin Chief Medical Officer Intent to Sell (Form 144) -1,590 $80.00 –
1 Sep 2026 Elizabeth Yeu-Lin Chief Medical Officer Automatic Disposition -11,578 $80.00 30,130
31 Aug 2026 Aziz Mottiwala Former Chief Commercial Officer Intent to Sell (Form 144) -77,698 $73.96 –
31 Aug 2026 Elizabeth Yeu-Lin Chief Medical Officer Intent to Sell (Form 144) -4,601 $73.86 –
24 Aug 2026 Aziz Mottiwala Former Chief Commercial Officer Intent to Sell (Form 144) -81,332 $71.85 –
18 Aug 2026 Aziz Mottiwala Former Chief Commercial Officer Intent to Sell (Form 144) -53,043 $72.00 –
24 Jun 2026 William Link Independent Director Other Derivative Acquisition +3,223 – 806

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 6,066,524 13.0% 6.9
15 Oct 2026 5,731,409 12.2% 5.7
30 Sep 2026 6,070,928 13.0% 8.3
15 Sep 2026 6,127,884 13.1% 6.6
31 Aug 2026 6,011,550 13.7% 9.8
14 Aug 2026 5,997,475 13.7% 7.5

Discussion

No comments yet — be the first to weigh in on TARS.

Sign in to join the discussion.

Scroll to Top